FDA grant Fast Track Designation for aviptadil for respiratory distress in COVID-19

Aviptadil is a synthetic form of human vasoactive intestinal peptide which reduces inflammation in the lungs and protects the alveolar type II cells that are believed to be an entry route for the SARS-CoV-2 to invade the lungs. A phase II/III study is currently underway.


Biospace Inc.